развитие детей с задержкой внутриутробного развития
Главное меню:
Интересное
развитие детей с задержкой внутриутробного развития, Biologics for eosinophilic oesophagitis: a systematic review , Current state of biologics in treating eosinophilic esophagitis, Biologics in the Treatment of Eosinophilic Esophagitis: Ready , Biologics in eosinophilic esophagitis - PubMed, Consumer’s Guide to Biologics for Eosinophilic Esophagitis, , .
Biologics targeting IL-5 have been exploited and investigated in EoE and other non-EoE EGIDs, such as mepolizumab, reslizumab, and benralizumab. Mepolizumab and reslizumab bind directly to the IL-5 molecule, interfering with its attachment to IL-5Rα expressed on the eosinophil cell surface. While Benralizumab targets the eosinophilic IL-5Rα chain expressed on the granulocyte membrane, blocking IL-5 access to its receptor [,]. However, Benralizumab has been discontinued by its manufacturer presently. In a recent randomized controlled trial (RCT) assessing Benralizumab, it was observed that although the medication alleviates hypereosinophilia by eliminating all circulating eosinophils in EoG, patients continued to exhibit persistent signs, symptoms, and biomarkers associated with EoG []. Our study revealed that EoE patients’ histologic remission and endoscopic improvement were both significantly enhanced by treatment with anti-IL-5 monoclonal antibodies. Nevertheless, the same effects were not observed in symptom evaluation. One possible explanation for the disparities in histological and symptomatic responses resulting from anti-IL-5 monoclonal antibody treatment is that the RCTs we included used different criteria to assess symptomatic responses. One example is the EoE Symptom Activity Index (EEsAI) score, which focuses on the symptoms of dysphagia, whereas the physician’s eosinophilic oesophagitis global assessment scores were used for analyses that focus on the overall assessment of patient symptoms. However, there is no consensus on which scores to use to assess these patients, so studies of the different scores used were summarized. Indeed, the assertion posited by Kliewer et al. in their study presents another plausible interpretation suggesting that the pathogenesis of EGIDs may not solely hinge on eosinophilic mechanisms. Instead, it underscores a predilection for a comprehensive type 2 immune targeting approach., The therapeutic efficacy of biologics for EoE and other non-EoE EGIDs is still under debate. Therefore, we aim to assess the efficacy and safety of biologics compared to a placebo in the treatment of EoE patients by performing a comprehensive meta-analysis of existing high-quality, double-blind randomized controlled trials (RCTs)., Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated. This review focuses on biologics therapy in EoE..
Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction.1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis.2,3 Standard treatments include proton-pump inhibitors (PPIs), swallowed topical , Recent findings: There has been an increasing number of biologics under consideration for EoE and several that have undergone clinical trials. mAbs that target specific effectors involved in the disease may offer additional clinical and histologic benefit. In addition, they offer a more benign adverse effect profile than traditional therapies., Some biologics are given intravenously (through a needle into a vein) and some by infusion at a clinic or other setting. The biologic approved for EoE is self-administered subcutaneously, into the , , , .